Status: Recruiting
A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia
This clinical trial will test the safety and efficacy of combining trametinib and azacitidine in patients with juvenile myelomonocytic leukemia (JMML). Newly diagnosed lower-risk JMML patients will receive trametinib and azacitidine. High-risk JMML patients will receive trametinib, azacitidine, fludarabine, and cytarabine.
Participants needed: 58
Trial details
Phase: Phase 1, Phase 2Age: 1-21Biological sex: AllType: InterventionalSponsor: Therapeutic Advances in Childhood Leukemia ConsortiumUpdated: Apr 15, 2026Locations: 19
Eligibility criteria
Peripheral blood monocyte count ≥ 1 × 109/L* [+28]
Patients cannot have a known allergy to any of the drugs used in the study. [+8]